Six new peptides.
Built compliant from day one.
BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax are now available to CareValidate storefronts. Each is provider-prescribed and compounded by U.S.-licensed 503A pharmacies under the conditions FDA published in October. The compliance work is done, so you can launch.
We’re bringing the new peptides to market, compliantly.
Plenty of companies are selling peptides. Far fewer can show where the ingredient came from, how it was tested, and who reviewed whether it was right for the patient. CareValidate built that infrastructure before the rules were final, so our storefronts can offer these six peptides with confidence.
Compliant Sourcing
Every peptide is compounded from bulk substance made in an FDA-registered facility, with a certificate of analysis that conforms to FDA's published specifications. No research-use-only material, ever.
503A Pharmacy Partners
Our U.S.-licensed 503A compounding partners meet CareValidate's credentialing standards. Prescriptions route directly to the pharmacy, with tracking visible in the platform.
Single-Ingredient Therapies
FDA's conditions allow one active ingredient per product. We build every protocol around that rule so your storefront never has to unwind a product later.
Clinical Protocols, Ready to Go
Intake forms, prescribing criteria and check-in cadence are physician-approved and built into the CareValidate flow. A licensed provider reviews every patient before anything is prescribed.
Safety Reporting Built In
FDA now requires adverse event and product quality reporting through MedWatch for these peptides. Our pharmacy partners have the reporting in place, and our platform supports the follow-up.
Launch on Your Existing Storefront
Add the new peptides alongside NAD+, Sermorelin, GHK-Cu, PT-141, Glutathione and GLP-1s. No new vendors, no new pharmacy contracts, no rebuild.
What's now available.
From interest to live on your storefront.
Register interest or book a demo
Existing clients register through the form below. New operators book a demo with our team to talk through fit, patient base and goals.
We configure your program
Our team adds the peptides you choose to your formulary and intake, confirms state availability, and reviews your marketing for claims compliance.
Patients start care
Patients complete a guided intake, a licensed provider reviews and prescribes if appropriate, and a 503A partner pharmacy fulfills and ships.
Ahead of the curve, on purpose.
When peptides started trending, we didn't rush product to market. We built the compliance layer first: a LegitScript-aligned formulary, vetted pharmacy partners, and a clear view of what FDA would require. That's why our storefronts can move now, while others are still sorting out sourcing.
These new six are just the beginning.
More peptides are slated for FDA review in 2027. As each one clears and compliant supply is available, we'll add it to the CareValidate formulary and notify storefronts directly.
Current formulary
NAD+, Sermorelin, GHK-Cu, PT-141 and Glutathione, plus GLP-1s for storefronts that want them.
Six new peptides
BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax.
The next wave
Additional peptides under FDA review. Timing depends on FDA and pharmacy supply.
How we expand: Each new peptide needs an FDA pathway, conforming bulk supply from an FDA-registered facility, and pharmacy partners ready to compound and report. CareValidate handles the sourcing, vetting, clinical protocols and platform setup — storefronts get access as each one goes live.
What storefronts need to know.
Compounded peptides are not FDA-approved and have not been reviewed by FDA for safety, effectiveness or quality. They are compounded under an interim FDA enforcement discretion policy that may change. Evidence on safety and effectiveness in humans is limited. Treatment requires evaluation by a licensed provider, who determines whether a prescription is appropriate. Availability varies by state.